Gene expression analysis from the STAM mouse model attributes Thykamine™ with dose-dependent anti-MASH, anti-inflammatory and anti-fibrosis molecular effects in liver QUÉBEC, Feb. 12, 2026 /PRNewswire ...

Century Health, a pioneer in applying AI to real-world clinical data to accelerate research, and Arizona Gastrointestinal Associates (AGA), an independent, physician-led gastroenterology network, ...

Findings from insitro's lead therapeutic CTRO-1013 program demonstrate that liver-targeted silencing of IRS1 lowered circulatory biomarkers associated with fibrosis progression and hepatocyte injury ...

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Novo Nordisk presented new Phase 3 ESSENCE data on ...

Data from a secondary analysis of the Phase 3 MAESTRO-NASH and MAESTRO-NAFLD-1 trials demonstrated that Rezdiffra improved key histologic MASH endpoints and significantly reduced multiple atherogenic ...

The AASLD late-breaking presentations will focus on the recent IMPACT Phase 2b readout of the 24-week data. In addition, Altimmune expects to announce 48-week data in Q4 2025. A copy of the ...

Altimmune (NASDAQ:ALT) lost ~64% in the premarket on Thursday after the company announced a mixed readout from a mid-stage trial for pemvidutide, its experimental therapy for a liver condition known ...

Concurrent improvement across key non-invasive tests underscores convergence of pemvidutide effects on MASH disease activity and fibrosis AI-based digital pathology analyses further demonstrate ...

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent chronic liver disease worldwide, and can rapidly progress to metabolic dysfunction-associated steatohepatitis (MASH).

QUEBEC, Feb. 19, 2026 /PRNewswire/ - Devonian Health Group Inc. ("Devonian" or the Company) (TSXV: GSD) (OTCQB: DVHGF) today announced positive results from a follow-up preclinical study evaluating ...

Secondary analysis from the Phase 3 MAESTRO-NASH and MAESTRO-NAFLD-1 trials examines improvements in lipid profiles for Lp(a), LDL-C and ApoB with Rezdiffra ® (resmetirom) Analysis of two-year data in ...